Boston Scientific said its first-quarter net income roughly doubled as demand continued to grow worldwide for its stents, catheters and other cardiology devices.

CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including electrophysiology and Watchman.

By Kamal Choudhury and Kunal Das April 22 (Reuters) - Medical device maker Boston Scientific slashed its annual profit and revenue growth forecasts on Wednesday, a move analysts said could reassure investors who had long called for a revision,

Boston Scientific Corporation secured net sales of $5.203 billion during the first quarter of 2026, growing 11.6% overall. The company’s guidance predicted 10.5% to 12% growth for the period. In addition, the company’s MedSurg segment posted 7.8% ...

April 22 () - Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, overshadowing a first-quarter earnings and revenue ‌beat, while its shares were little changed after earlier volatility.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and reminds investors of the May 4,

Boston Scientific shared the results during a late-breaking presentation at this year’s EHRA congress in Paris, France.

Boston Scientific (BSX) drops 36% YTD to $60.54 as analysts lower targets ahead of Q1 earnings. Despite cuts, firms maintain Buy ratings with upside potential.

Shares of leading cardiovascular and medsurg (medical-surgical) technologies provider Boston Scientific (NYSE: BSX) are down 16% as of noon ET on Wednesday, following its fourth-quarter earnings report. Boston Scientific grew sales and adjusted earnings ...

Boston Scientific (NYSE:BSX) today announced a €75 million (approximately $88.4 million) investment at its Galway, Ireland, site.

Boston Scientific Corporation BSX reported first-quarter 2026 revenues of $5.20 billion on Wednesday, slightly better than the consensus estimate of $5.17 billion, beating the management guidance of $5.22 billion-$5.31 billion. Sales increased 11.6% on a ...